Measuring Glymphatic Flow in Man Using Quantitative Contrast-Enhanced MRI

R Watts; J M Steinklein; L Waldman; X Zhou; C G Filippi

doi:10.3174/ajnr.A5931

Measuring Glymphatic Flow in Man Using Quantitative Contrast-Enhanced MRI

AJNR Am J Neuroradiol. 2019 Apr;40(4):648-651. doi: 10.3174/ajnr.A5931. Epub 2019 Jan 24.

Authors

R Watts¹, J M Steinklein², L Waldman², X Zhou², C G Filippi³

Affiliations

¹ From the Department of Radiology (R.W.), University of Vermont, Burlington, Vermont.
² Department of Radiology (J.M.S., L.W., X.Z., C.G.F.), Lenox Hill Hospital and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, East Garden City, New York.
³ Department of Radiology (J.M.S., L.W., X.Z., C.G.F.), Lenox Hill Hospital and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, East Garden City, New York. cfilippi@northwell.edu sairaallapeikko@gmail.com.

Abstract

On the basis of animal models, glymphatic flow disruption is hypothesized to be a factor in the development of Alzheimer's disease. We report the first quantitative study of glymphatic flow in man, combining intrathecal administration of gadobutrol with serial T1 mapping to produce contrast concentration maps up to 3 days postinjection, demonstrating performing a quantitative study using the techniques described feasibility and providing data on pharmacokinetics.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Brain
Contrast Media / administration & dosage
Glymphatic System / diagnostic imaging*
Humans
Image Processing, Computer-Assisted / methods
Injections, Spinal
Magnetic Resonance Imaging / methods*
Male
Middle Aged
Neuroimaging / methods*
Organometallic Compounds / administration & dosage

Substances

Contrast Media
Organometallic Compounds
gadobutrol